Azenta, Inc. AZTA
We take great care to ensure that the data presented and summarized in this overview for Azenta, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AZTA
View all-
Vanguard Group Inc Valley Forge, PA5.35MShares$273 Million0.01% of portfolio
-
Kayne Anderson Rudnick Investment Management LLC Los Angeles, CA5.2MShares$265 Million0.75% of portfolio
-
Black Rock Inc. New York, NY5.08MShares$259 Million0.01% of portfolio
-
Politan Capital Management LP New York, NY4.61MShares$235 Million14.46% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.55MShares$130 Million0.04% of portfolio
-
State Street Corp Boston, MA1.74MShares$88.5 Million0.0% of portfolio
-
Gw&K Investment Management, LLC Boston, MA1.52MShares$77.5 Million0.81% of portfolio
-
Conestoga Capital Advisors, LLC1.28MShares$65.4 Million1.13% of portfolio
-
Allspring Global Investments Holdings, LLC1.06MShares$54 Million0.1% of portfolio
-
Macquarie Group LTD Australia, C31.06MShares$53.9 Million0.07% of portfolio
Latest Institutional Activity in AZTA
Top Purchases
Top Sells
About AZTA
Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.
Insider Transactions at AZTA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 20
2024
|
Violetta Hughes VP, Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
584
-15.59%
|
$29,784
$51.36 P/Share
|
|
Apr 01
2024
|
Jason Joseph SVP, General Counsel, Secy. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,000
-1.06%
|
$60,000
$60.15 P/Share
|
|
Mar 08
2024
|
Jason Joseph SVP, General Counsel, Secy. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,000
-4.08%
|
$268,000
$67.5 P/Share
|
|
Mar 07
2024
|
Jason Joseph SVP, General Counsel, Secy. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,000
-2.88%
|
$585,000
$65.14 P/Share
|
|
Feb 12
2024
|
Frank Casal |
BUY
Grant, award, or other acquisition
|
Direct |
3,603
+27.73%
|
$234,195
$65.93 P/Share
|
|
Feb 12
2024
|
Tina Susan Nova |
SELL
Grant, award, or other acquisition
|
Direct |
2,465
-28.88%
|
$160,225
$65.93 P/Share
|
|
Feb 12
2024
|
Didier Hirsch |
BUY
Grant, award, or other acquisition
|
Direct |
2,465
+50.0%
|
$160,225
$65.93 P/Share
|
|
Feb 12
2024
|
Edward Peter Bousa |
SELL
Grant, award, or other acquisition
|
Direct |
2,465
-50.0%
|
$160,225
$65.93 P/Share
|
|
Feb 12
2024
|
Erica Mc Laughlin |
BUY
Grant, award, or other acquisition
|
Direct |
2,465
+16.13%
|
$160,225
$65.93 P/Share
|
|
Feb 12
2024
|
Martin D Madaus |
BUY
Grant, award, or other acquisition
|
Direct |
2,465
+50.0%
|
$160,225
$65.93 P/Share
|
|
Feb 12
2024
|
Michael Rosenblatt |
BUY
Grant, award, or other acquisition
|
Direct |
2,465
+15.9%
|
$160,225
$65.93 P/Share
|
|
Feb 12
2024
|
Robyn C Davis |
BUY
Grant, award, or other acquisition
|
Direct |
2,465
+7.69%
|
$160,225
$65.93 P/Share
|
|
Feb 01
2024
|
Robin Vacha SVP, GM Life Science Products |
BUY
Grant, award, or other acquisition
|
Direct |
324
+1.03%
|
$12,636
$39.41 P/Share
|
|
Feb 01
2024
|
Ginger Zhou SVP and General Manager, Genom |
BUY
Grant, award, or other acquisition
|
Direct |
448
+3.35%
|
$17,472
$39.41 P/Share
|
|
Jan 31
2024
|
Violetta Hughes VP, Chief Accounting Officer |
SELL
Grant, award, or other acquisition
|
Direct |
311
-7.67%
|
$20,215
$65.2 P/Share
|
|
Dec 05
2023
|
Robin Vacha SVP, GM Life Science Products |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,175
-16.71%
|
$289,800
$56.6 P/Share
|
|
Dec 01
2023
|
David Dong Wang SVP & GM, SMS |
SELL
Sale (or disposition) back to the issuer
|
Direct |
138
-1.44%
|
$7,866
$57.96 P/Share
|
|
Nov 17
2023
|
David C Gray Chief Strategy & New Business |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,179
-6.47%
|
$279,666
$54.83 P/Share
|
|
Nov 16
2023
|
Lindon G Robertson EVP & Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,779
-2.24%
|
$147,287
$53.81 P/Share
|
|
Nov 16
2023
|
Stephen S Schwartz CEO |
BUY
Grant, award, or other acquisition
|
Direct |
22,448
+4.79%
|
$1,212,192
$54.57 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 112K shares |
|---|
| Grant, award, or other acquisition | 31.4K shares |
|---|---|
| Sale (or disposition) back to the issuer | 48.1K shares |
| Open market or private sale | 17.6K shares |